Role of Multidisciplinary Team Meetings in the Diagnosis and Management of Diffuse Parenchymal Lung Diseases in a Tertiary Care Hospital

Abstract

Background Decisions on the management of interstitial lung diseases (ILD) and prognostication require an accurate diagnosis. It has been proposed that multidisciplinary team (MDT) meetings for ILD (ILD-MDT) improve these decisions in challenging cases of ILD. However, most studies in this field have been based on the decisions of individual clinicians and there are few reports on the outcomes of the ILD-MDT approach. We therefore describe the experience of the ILD-MDT meetings at our institution.

Methods A single-center retrospective review of the electronic health care records of patients discussed in the ILD-MDT meetings at our institution from February 2016 to January 2021 was performed. At out institution, at each ILD-MDT meeting, the referring pulmonologist presents the clinical history and the results of all relevant investigations including serology, blood gas analyses, lung function tests, bronchoscopy, and bronchoalveolar lavage. A radiologist then describes the imaging including serial computed tomography (CT) scans. When available, the findings on lung biopsy are presented by a pathologist. Subsequent discussions lead to a consensus on the diagnosis and further management.

Results The study included 121 patients, comprising 71 (57%) males and 76 nonsmokers (62.8%), with a mean age of 65 years (range: 25–93 years). The average number of comorbidities was 2.4 (range: 0–7). Imaging-based diagnoses were usual interstitial pneumonia (UIP)/chronic hypersensitivity pneumonitis (CHP) in 32 (26%) patients, UIP in 20 (17%) patients, probable UIP in 27 (22%) patients, nonspecific interstitial pneumonia in 11 (9%) patients, and indeterminate interstitial lung abnormalities (ILA) in 10 (8%) patients. The most common consensus clinical diagnosis after an ILD-MDT discussion was chronic hypersensitivity pneumonitis/idiopathic pulmonary fibrosis in 17 patients (14%), followed by idiopathic pulmonary fibrosis and connective tissue disease associated interstitial lung disease in 16 patients (13%), CHP in 11 patients (9.1%), and ILA in 10 patients (8.4%). Only a 42 patients (35%) required surgical lung biopsy for confirmation of the diagnosis.

Conclusion This study describes the characteristics of the patients discussed in the ILD-MDT meetings with emphasis on their clinical, radiological, and laboratory data to reach a diagnosis and management plan. The decisions on commencement of antifibrotics or immunosuppressive therapy for patients with various ILDs are also made during these ILD-MDT meetings. This descriptive study could help other health care professionals regarding the structure of their ILD-MDT meetings and with discussions about diagnostic and care decisions for diffused parenchymal lung disease patients.

Keywords

multidisciplinary team - diffused parenchymal lung diseases - interstitial lung disease - idiopathic pulmonary fibrosis - usual interstitial pneumonia - chronic hypersensitivity pneumonitis

Ethical Approval

The institutional review board of our institution approved this study.

Publication History

Article published online:
01 November 2023

• References

• 1 Samarelli AV, Tonelli R, Marchioni A. et al. Fibrotic idiopathic interstitial lung disease: the molecular and cellular key players. Int J Mol Sci 2021; 22 (16) 8952
• 2 Raghu G, Remy-Jardin M, Myers JL. et al; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198 (05) e44-e68
• 3 Jo HE, Glaspole IN, Levin KC. et al. Clinical impact of the interstitial lung disease multidisciplinary service. Respirology 2016; 21 (08) 1438-1444
• 4 Walsh SLF, Maher TM, Kolb M. et al; IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. Eur Respir J 2017; 50 (02) 1700936
• 5 Alhamad EH. Interstitial lung diseases in Saudi Arabia: a single-center study. Ann Thorac Med 2013; 8 (01) 33-37
• 6 Sherbini N, Feteih MN, Wali SO, Alamoudi OS, Al-Faifi SM, Khalid I. Idiopathic pulmonary fibrosis in Saudi Arabia: demographic, clinical, and survival data from two tertiary care hospitals. Ann Thorac Med 2014; 9 (03) 168-172
• 7 Flaherty KR, King Jr TE, Raghu G. et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. Am J Respir Crit Care Med 2004; 170 (08) 904-910
• 8 Thomeer M, Demedts M, Behr J. et al; Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study group. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J 2008; 31 (03) 585-591
• 9 Aziz ZA, Wells AU, Hansell DM. et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax 2004; 59 (06) 506-511
• 10 Raghu G, Collard HR, Egan JJ. et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183 (06) 788-824
• 11 Wells AU, Costabel U, Poletti V. et al. Challenges in IPF diagnosis, current management and future perspectives. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32 (1, Suppl 1): 28-35
• 12 Blackhall V, Asif M, Renieri A. et al. The role of surgical lung biopsy in the management of interstitial lung disease: experience from a single institution in the UK. Interact Cardiovasc Thorac Surg 2013; 17 (02) 253-257
• 13 Ageely G, Souza C, De Boer K, Zahra S, Gomes M, Voduc N. the impact of multidisciplinary discussion (MDD) in the diagnosis and management of fibrotic interstitial lung diseases. Can Respir J 2020; 2020: 9026171
• 14 Lynch DA, Sverzellati N, Travis WD. et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper. Lancet Respir Med 2018; 6 (02) 138-153
• 15 Raghu G, Remy-Jardin M, Richeldi L. et al. idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2022; 205 (09) e18-e47
• 16 De Sadeleer LJ, Meert C, Yserbyt J. et al. Diagnostic ability of a dynamic multidisciplinary discussion in interstitial lung diseases: a retrospective observational study of 938 cases. Chest 2018; 153 (06) 1416-1423
• 17 Burge PS, Reynolds J, Trotter S, Burge GA, Walters G. Histologist's original opinion compared with multidisciplinary team in determining diagnosis in interstitial lung disease. Thorax 2017; 72 (03) 280-281
• 18 Ryerson CJ, Urbania TH, Richeldi L. et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013; 42 (03) 750-757
• 19 Troy L, Glaspole I, Goh N. et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2014; 43 (05) 1529-1530
• 20 Skolnik K, Ryerson CJ. Unclassifiable interstitial lung disease: a review. Respirology 2016; 21 (01) 51-56
• 21 Walsh SLF. . Multidisciplinary evaluation of interstitial lung diseases: current insights: number 1 in the Series “Radiology” edited by Nicola Sverzellati and Sujal Desai. Eur Respir Rev 2017; 26 (144) 170002
• 22 Traila D, Oancea C, Tudorache E, Mladinescu OF, Timar B, Tudorache V. Clinical profile of unclassifiable interstitial lung disease: comparison with chronic fibrosing idiopathic interstitial pneumonias. J Int Med Res 2018; 46 (01) 448-456
• 23 Morell F, Villar A, Montero MÁ. et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013; 1 (09) 685-694
• 24 Biglia C, Ghaye B, Reychler G. et al. Multidisciplinary management of interstitial lung diseases: a real-life study. Sarcoidosis Vasc Diffuse Lung Dis 2019; 36 (02) 108-115
• 25 Richeldi L, Launders N, Martinez F. et al. The characterization of interstitial lung disease multidisciplinary team meetings: a global study. ERJ Open Res 2019; 5 (02) 00209-2018
• 26 Murali Mohan BV, Tousheed SZ, Manjunath PH. et al. Multidisciplinary team obviates biopsy in most patients with diffuse parenchymal lung diseases: a retrospective study from India. Clin Respir J 2021; 15 (07) 761-769
• 27 Walsh SLF, Wells AU, Desai SR. et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med 2016; 4 (07) 557-565
• 28 Barratt SL, Morales M, Speirs T. et al. Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needs. BMJ Open Respir Res 2018; 5 (01) e000360
• 29 Jo HE, Corte TJ, Moodley Y. et al. Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres. BMC Pulm Med 2016; 16: 22
• 30 Dowman LM, McDonald CF, Hill CJ. et al. The evidence of benefits of exercise training in interstitial lung disease: a randomized controlled trial. Thorax 2017; 72 (07) 610-619
• 31 Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet 2022; 400 (10354): 769-786